INOTUZUMAB OZOGAMICIN FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL: EFFICACY AND SAFETY BY PRIOR THERAPY

被引：0
|
作者：
DeAngelo, D. J. [1 ]
Jabbour, E. J. [2 ]
Stelljes, M. [3 ]
Liedtke, M. [4 ]
Stock, W. [5 ]
Goekbuget, N. [6 ]
Martinelli, G. [7 ]
O'Brien, S. [8 ]
Wang, K. [9 ]
Wang, T. [10 ]
Paccagnella, M. L. [10 ]
Sleight, B. [10 ]
Vandendries, E. [11 ]
Advani, A. S. [12 ]
Kantarjian, H. M. [2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Klinikum mUNSTER, Munster, Germany
[4] Stanford Canc Ctr, Stanford, CA USA
[5] Univ Chicago Med, Chicago, IL USA
[6] Univ Hosp Frankfurt, Frankfurt, Germany
[7] Univ Bologna, Bologna, Italy
[8] Univ Calif Irvine, Orange, CA 92668 USA
[9] Pfizer Inc, Pearl River, NY USA
[10] Pfizer Inc, Groton, CT 06340 USA
[11] Pfizer Inc, Cambridge, MA USA
[12] Cleveland Clin Main Campus, Cleveland, OH USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S499
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [41] Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Tragiannidis, Athanasios
    Antari, Vassiliki
    Tsotridou, Eleni
    Sidiropoulos, Theodoros
    Kaisari, Aikaterini
    Palabougiouki, Maria
    Vyzantiadis, Timoleon-Achilleas
    Hatzipantelis, Emmanuel
    Galli-Tsinopoulou, Assimina
    Goussetis, Evgenios
    HEMATOLOGY REPORTS, 2024, 16 (04) : 579 - 584
  • [42] A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
    Brivio, Erica
    Locatelli, Franco
    Lopez-Yurda, Marta
    Malone, Andrea
    Diaz-de-Heredia, Cristina
    Bielorai, Bella
    Rossig, Claudia
    van der Velden, Vincent H. J.
    Ammerlaan, Anneke C. J.
    Thano, Adriana
    van der Sluis, Inge M.
    den Boer, Monique L.
    Chen, Ying
    Sleight, Barbara
    Brethon, Benoit
    Nysom, Karsten
    Sramkova, Lucie
    Ora, Ingrid
    Vinti, Luciana
    Chen-Santel, Christiane
    Zwaan, Christian Michel
    BLOOD, 2021, 137 (12) : 1582 - 1590
  • [43] Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
    Badar, Talha
    Szabo, Aniko
    Dinner, Shira
    Liedtke, Michaela
    Burkart, Madelyn
    Shallis, Rory M.
    Yurkiewicz, Ilana R.
    Kuo, Eric
    Khan, Muhammad Ali
    Balasubramanian, Suresh
    Yang, Jay
    Hefazi, Mehrdad
    Podoltsev, Nikolai
    Patel, Anand
    Curran, Emily
    Wang, Amy
    Arslan, Shukaib
    Aldoss, Ibrahim
    Siebenaller, Caitlin
    Mattison, Ryan J.
    Litzow, Mark R.
    Wadleigh, Martha
    Advani, Anjali S.
    Atallah, Ehab
    CANCER, 2021, 127 (07) : 1039 - 1048
  • [44] Phase I Study of Inotuzumab Ozogamicin in Children with Relapsed/Refractory CD22-Positive Acute Lymphoblastic Leukemia in Japan (Ino-Ped-All-1)
    Nakayama, Hideki
    Ogawa, Chitose
    Sekimizu, Masahiro
    Fujisaki, Hiroyuki
    Kosaka, Yoshiyuki
    Hashimoto, Hiroya
    Saito, Akiko
    Horibe, Keizo
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [45] Effect of Renal and/or Hepatic Impairment on the Pharmacokinetics and Safety of Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
    Garrett, May
    Kantarjian, Hagop M.
    DeAngelo, Daniel J.
    Boni, Joseph
    BLOOD, 2017, 130
  • [46] Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
    Jain, Nitin
    Maiti, Abhishek
    Ravandi, Farhad
    Konopleva, Marina
    Daver, Naval
    Kadia, Tapan
    Pemmaraju, Naveen
    Short, Nicholas
    Kebriaei, Partow
    Ning, Jing
    Cortes, Jorge
    Jabbour, Elias
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) : 1000 - 1007
  • [47] Hospitalization for patients in the United States (US) and European Union (EU) treated with inotuzumab ozogamicin (InO) vs standard of care (SOC) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in a global phase 3 trial.
    Su, Yun
    Van Oostrum, Ilse
    Vandendries, Erik
    Welch, Verna
    Loberiza, Fausto Rodriguez
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome-positive (Ph plus ) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
    Stock, Wendy
    Martinelli, Giovanni
    Stelljes, Matthias
    DeAngelo, Daniel J.
    Gokbuget, Nicola
    Advani, Anjali S.
    O'Brien, Susan Mary
    Liedtke, Michaela
    Merchant, Akil Abid
    Cassaday, Ryan Daniel
    Wang, Tao
    Vandendries, Erik
    Marks, David I.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
    Kantarjian, Hagop M.
    Stock, Wendy
    Cassaday, Ryan D.
    DeAngelo, Daniel J.
    Jabbour, Elias
    O'Brien, Susan M.
    Stelljes, Matthias
    Wang, Tao
    Paccagnella, M. Luisa
    Nguyen, Kevin
    Sleight, Barbara
    Vandendries, Erik R.
    Neuhof, Alexander
    Laird, A. Douglas
    Advani, Anjali S.
    BLOOD, 2019, 134
  • [50] Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
    DeAngelo, Daniel J.
    Stock, Wendy
    Stein, Anthony S.
    Shustov, Andrei
    Liedtke, Michaela
    Schiffer, Charles A.
    Vandendries, Erik
    Liau, Katherine
    Ananthakrishnan, Revathi
    Boni, Joseph
    Laird, A. Douglas
    Fostvedt, Luke
    Kantarjian, Hagop M.
    Advani, Anjali S.
    BLOOD ADVANCES, 2017, 1 (15) : 1167 - 1180
12345